Skip to main content

Anti-Rheumatic Rx

      In abstract 0001 presented at ACR22 Convergence, researchers presented 12-month data from a randomized double-blind placebo-controlled trial of pegloticase with or without MTX.
      The last day was jammed with important reports and research including the late breaking abstracts.   
      RT @RichardPAConway: Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commeric

      Richard Conway RichardPAConway

      2 years 7 months ago
      Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commerically-insured patients. 20-44%! of new prescriptions not filled by 6 months. Higher for csDMARDs than b/tsDMARDs @RheumNow #ACR22 Abstr#2199 https://t.co/Pwg6GKu7Gg https://t.co/wPF0pu1UDa
      RT @drdavidliew: Which is better for CV risk in RA:
      triple therapy DMARDs or TNFi?

      TARGET study
      n=159 using PET/CT sur

      David Liew drdavidliew

      2 years 7 months ago
      Which is better for CV risk in RA: triple therapy DMARDs or TNFi? TARGET study n=159 using PET/CT surrogate (endpoint responsivenessđź‘€) - either led to benefit - both equally good - benefit *not* linked to change in DAS28 A direct CV effect of RA Rx? ABST2215 #ACR22 @RheumNow https://t.co/4FPvSbfGsD
      RT @RichardPAConway: Bass et al. Treatment ICI-arthritis. Tricky one. MTX alone assoc longer time to cancer progression

      Richard Conway RichardPAConway

      2 years 7 months ago
      Bass et al. Treatment ICI-arthritis. Tricky one. MTX alone assoc longer time to cancer progression and to arthritis control compared to combination with bDMARD. Thoughts @drdavidliew ? @RheumNow #ACR22 Abstr#1669 https://t.co/8KH8RZzcaZ https://t.co/DtpA8s4PLy
      RT @doctorRBC: Are your SpA pts planning on conceiving? Be careful with NSAID use
      French study found age and NSAID use a

      Robert B Chao, MD doctorRBC

      2 years 7 months ago
      Are your SpA pts planning on conceiving? Be careful with NSAID use French study found age and NSAID use associated with longer time-to-conception. Factors not associated: smoking, BASDAI score, DMARD use #ACRBest Abs#1673 @RheumNow #ACR22 https://t.co/D63XTY7IB8
      RT @EBRheum: Important late breaker re:barriers to MTX post Roe decision

      6% of respondents who tried to fill MTX had ba

      Mike Putman EBRheum

      2 years 7 months ago
      Important late breaker re:barriers to MTX post Roe decision 6% of respondents who tried to fill MTX had barriers to access; most commonly related to pharmacies/pharmacists This number should be 0%!! #ACR22 abstr#L09 @RheumNow https://t.co/dgZkJLlL25
      RT @drdavidliew: Steroid-sparing in PMR: methotrexate most used, but what is the evidence?

      Christian Dejaco says: varia

      David Liew drdavidliew

      2 years 7 months ago
      Steroid-sparing in PMR: methotrexate most used, but what is the evidence? Christian Dejaco says: variable at best. We need a proper RCT - and it’s on its way. @Sarah_L_Mackie @profbdasgupta @DrMaxYates1 @CatherineL_Hill @drceowen #ACR22 @RheumNow https://t.co/dxaPdVcOPQ
      RT @RichardPAConway: Lillegraven @SiriLillegraven ARCTIC REWIND. RA patients flare-free on half-dose csDMARD x 12 months

      Richard Conway RichardPAConway

      2 years 7 months ago
      Lillegraven @SiriLillegraven ARCTIC REWIND. RA patients flare-free on half-dose csDMARD x 12 months - randomised to continue or stop. Flare 38% vs 17% over 12 months. DAS remission 96% vs 90%. Absence radiograph prog 84% vs 69% @RheumNow #ACR22 Abstr#2013 https://t.co/uOwd8Io5wZ https://t.co/SKWPE7GBrx
      NSAIDs and CV risk in Inflammatory Arthritis

      Dr. Richard Conway discusses abstract 1207, being presented #ACR22 meetin

      Dr. John Cush RheumNow

      2 years 7 months ago
      NSAIDs and CV risk in Inflammatory Arthritis Dr. Richard Conway discusses abstract 1207, being presented #ACR22 meeting. https://t.co/CjU2YbA3tk https://t.co/bHE4xw2IRF
      RT @RichardPAConway: Krijbolder et al. TREAT EARLIER DBRCT. MTX vs PBO for pre-RA. Treat 1 year, stop, and follow 1 year

      Richard Conway RichardPAConway

      2 years 7 months ago
      Krijbolder et al. TREAT EARLIER DBRCT. MTX vs PBO for pre-RA. Treat 1 year, stop, and follow 1 year. No difference in RA development. Delay in ACPA+ or high risk. Sustained benefit in MTX group on pain, EMS, function, MRI. @RheumNow #ACR22 Abstr#1603 https://t.co/M2qQfgrhC1 https://t.co/UUeknTLx0K
      Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more. Here are the RheumNow faculty selections for #ACRbest abstracts today:
      ×